Cancer

Immuno-oncology breakthroughs: from precision medicine to modulating the tumor microenvironment

The European Association for Cancer Research (EACR) explores the most exciting cancer research from Europe and globally. Clarivate Life Sciences Editor Joan Tur reviews the top three trends from their recent immuno-oncology event, and their implications for the future of cancer treatment. Despite pandemic-driven clinical trial delays across multiple therapy areas, novel immuno-oncology approaches continue […]

First-in-class Tazverik launched for rare sarcoma, wider use will drive market value

Epizyme’s first-in-class EZH2 (enhancer of zeste homolog 2) inhibitor Tazverik (tazemetostat) has become the first therapy to be made available in the U.S. for the treatment of epithelioid sarcoma (ES), a rare soft tissue tumor with a significant unmet need.1,2,3 The drug was granted accelerated approval in January 2020 for the treatment of patients aged […]

Oncology landscape stays hot for dealmakers

Intense competition for dealmaking in oncology “shows no sign of abating.” That’s the key takeaway from recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article, “Oncology dealmaking trends”, was featured in the Biopharma Dealmakers supplement to Nature Biotechnology and Nature Reviews: Drug Discovery. Munro, global practice leader, portfolio and licensing, […]

Immuno-oncology spotlight on diverse therapeutic classes

Immune checkpoint inhibitors, such as the multi-billion-dollar drugs Keytruda and Opdivo, have dominated the immuno-oncology landscape in recent years (see Figure 1), but are not the only classes on the market or in development. T-cell engager therapeutics, oncolytic virus therapy and adoptive T-cell therapies were among the promising technologies covered at the fourth annual Immuno-Oncology […]

In multiple myeloma, B-cell maturation antigen emerges as promising target

This is a Cortellis Market Insight report, an ongoing series featuring expert reviews of hot topics in the biopharma field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis were gathered from Cortellis from Clarivate Analytics. There remains an unmet need for patients with multiple myeloma (MM), particularly […]

FDA draft guidance addresses inclusion of adolescents in oncology trials

With an eye toward helping industry, investigators and institutional review boards (IRBs), the U.S. Food and Drug Administration (FDA) has unveiled draft guidance on the inclusion of adolescents—defined as those between the ages of 12 and 17—in adult oncology trials. Allowing adolescents in relevant trials would allow for earlier access to life-saving drugs in this […]

ASCO 2018: paradigm changers and emerging blockbusters

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis was gathered both onsite at ASCO and from Clarivate Analytics Cortellis. The American Society for Clinical Oncology […]

ESMO session explores CDK inhibition and cell cycle modulation in cancer

The principles of CDKs/cyclins in cell-cycle progression Deregulation of the cell cycle is a common feature of human cancer. The mammalian cell cycle is controlled by a subfamily of cyclin-dependent kinases (CDKs), the activity of which is modulated by several activators (cyclins) and inhibitors (INK4, and WAF1/KIP inhibitors). The activity of cell cycle CDKs is […]

PolyPEPI-1018: A hopeful advance in the fight against cancer – and a milestone for us

Meet PolyPEPI-1018, a cancer vaccine being developed by Treos Bio Ltd. for the treatment of metastatic colorectal cancer. PolyPEPI-1018 contains six synthetic polypeptides that are precisely selected to induce immune cell responses against 12 epitopes from seven cancer testis antigens (CTAs) most frequently expressed in colorectal cancers. These polypeptides are optimized with the PEPI biomarker […]

Accelerating – and maintaining – drug approvals in the U.S.

Bringing a drug to market is the ultimate milestone for any pharmaceutical firm that has invested significant effort, not to mention time and resources, into developing its product. But all that work and outlay does not stop at marketing approval—this achievement must be maintained. There can be various regulatory requirements that a firm must meet […]